title: A systematic in silico search for target similarity identifies several approved drugs with potential activity against the Plasmodium falciparum apicoplast.
abstract: Most of the drugs in use against Plasmodium falciparum share similar modes of action and, consequently, there is a need to identify alternative potential drug targets. Here, we focus on the apicoplast, a malarial plastid-like organelle of algal source which evolved through secondary endosymbiosis. We undertake a systematic in silico target-based identification approach for detecting drugs already approved for clinical use in humans that may be able to interfere with the P. falciparum apicoplast. The P. falciparum genome database GeneDB was used to compile a list of ≈600 proteins containing apicoplast signal peptides. Each of these proteins was treated as a potential drug target and its predicted sequence was used to interrogate three different freely available databases (Therapeutic Target Database, DrugBank and STITCH3.1) that provide synoptic data on drugs and their primary or putative drug targets. We were able to identify several drugs that are expected to interact with forty-seven (47) peptides predicted to be involved in the biology of the P. falciparum apicoplast. Fifteen (15) of these putative targets are predicted to have affinity to drugs that are already approved for clinical use but have never been evaluated against malaria parasites. We suggest that some of these drugs should be experimentally tested and/or serve as leads for engineering new antimalarials.
authors.affiliation: Instituto de Patologia Tropical e Saúde Pública/Universidade Federal de Goiás/Goiânia, Brazil.
authors.forename: Nadlla Alves
authors.initials: NA
authors.lastname: Bispo
authors.forename: Richard
authors.initials: R
authors.lastname: Culleton
authors.forename: Lourival Almeida
authors.initials: LA
authors.lastname: Silva
authors.forename: Pedro
authors.initials: P
authors.lastname: Cravo
mesh_terms: D000962:Antimalarials / Q000737:chemistry* / Q000494:pharmacology; D003198:Computer Simulation; D030541:Databases, Genetic; D062313:Databases, Pharmaceutical; D015195:Drug Design; D005786:Gene Expression Regulation; D008956:Models, Chemical; D058990:Molecular Targeted Therapy; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D018087:Plastids / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D021382:Protein Sorting Signals / Q000235:genetics; D015800:Protozoan Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry*
chemical_list: D000962:Antimalarials; D021382:Protein Sorting Signals; D015800:Protozoan Proteins
references.citation: Science. 1999 Sep 3;285(5433):1573-6
references.pmid: 10477522
references.citation: Cell Mol Life Sci. 2006 Jul;63(14):1586-96
references.pmid: 16699808
references.citation: Antimicrob Agents Chemother. 1999 May;43(5):1042-51
references.pmid: 10223912
references.citation: AAPS PharmSciTech. 2010 Jun;11(2):538-49
references.pmid: 20339959
references.citation: Acta Derm Venereol Suppl (Stockh). 1989;143:75-82
references.pmid: 2475996
references.citation: Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36
references.pmid: 21948793
references.citation: ChemMedChem. 2009 Aug;4(8):1317-26
references.pmid: 19472268
references.citation: Mol Pharmacol. 1981 Jul;20(1):218-23
references.pmid: 6793844
references.citation: J Antimicrob Chemother. 2006 Mar;57(3):489-97
references.pmid: 16415127
references.citation: Chem Rev. 2012 Mar 14;112(3):1269-83
references.pmid: 22026508
references.citation: Sci Rep. 2011;1:9
references.pmid: 22355528
references.citation: Dig Dis. 1992;10(3):153-61
references.pmid: 1611711
references.citation: Fundam Clin Pharmacol. 2003 Apr;17(2):147-53
references.pmid: 12667224
references.citation: FEMS Immunol Med Microbiol. 2010 Feb;58(1):61-74
references.pmid: 20041948
references.citation: Nucleic Acids Res. 2012 Jan;40(Database issue):D876-80
references.pmid: 22075997
references.citation: PLoS One. 2011;6(6):e20633
references.pmid: 21695207
references.citation: Curr Pharm Des. 2008;14(9):855-71
references.pmid: 18473835
references.citation: Prog Drug Res. 1974;18:15-24
references.pmid: 4616261
references.citation: Nature. 2008 Feb 21;451(7181):959-63
references.pmid: 18288187
references.citation: Antimicrob Agents Chemother. 1995 Mar;39(3):707-13
references.pmid: 7793877
references.citation: Drugs. 1991 Sep;42(3):379-405
references.pmid: 1720380
references.citation: J Natl Cancer Inst. 2010 Dec 15;102(24):1855-73
references.pmid: 21088277
references.citation: Infect Agents Dis. 1994 Feb;3(1):29-37
references.pmid: 7952925
references.citation: Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):873-8
references.pmid: 3309832
references.citation: Nat Rev Microbiol. 2004 Mar;2(3):203-16
references.pmid: 15083156
references.citation: Am J Med. 1991 Aug 8;91(2A):58S-63S
references.pmid: 1715673
references.citation: Nature. 1996 Jun 6;381(6582):482
references.pmid: 8632819
references.citation: Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41
references.pmid: 21059682
references.citation: J Biol Chem. 2003 Dec 26;278(52):53123-30
references.pmid: 14559907